TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR.

•The effects of therapy with pegylated interferon alpha 2a (PEG-IFN) were evaluated in patients with hepatitis delta virus genotype 3 (HDV-3) and these were correlated with a possible cure rate higher than expected.•The therapeutic protocol used in this study presented a satisfactory response level in terms of the proportion of treated subjects with a virological response.•HDV patients in the Amazon region can be treated with a combination of PEG-IFN and entecavir for 48 weeks, with a good chance of negative HDV RNA at week 24.•The results suggest that HDV-3 in the native population may be an ‘easy to treat’ variant compared to HDV-1.